The thesis

CARL develops AI-enabled personalized spine surgery solutions with 58.2% revenue growth. The company's net margin is -5880.0%, indicating significant investment in growth. Analyst consensus is BUY, despite a conviction score of 38/100. This setup is interesting due to the contrast between growth and profitability metrics.

Why now

The current macro moment, with the US-China squeeze on chip tools, highlights the importance of innovative medical technology. CARL's revenue growth and AI-enabled solutions make it a compelling watchlist candidate, particularly with a DCF intrinsic value of $86.

What to watch

Revenue growth and net margin improvements will be key indicators of CARL's success over the next 1-3 quarters. The company's ability to achieve profitability and maintain its growth trajectory will be crucial in confirming or denying the thesis.

Key risks

Valuation risk is high due to the negative P/E ratio of -10.5x and significant net losses. Execution risk is also a concern, as the company must balance growth with profitability. Macro risk from the US-China trade tensions may impact the company's supply chain and growth prospects.